英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Niraparib and abiraterone acetate plus prednisone for HRR . . .
    We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
  • Prostate Cancer, Version 3. 2026, NCCN Clinical Practice . . .
    The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Prostate Cancer, Version 3. 2026 - jnccn. org
    Abstract The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the dis-ease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmeta-static castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Efficacy and safety of treatments for metastatic castration . . .
    Metastatic prostate cancer that has not previously been treated with ADT is considered to be castration-sensitive prostate cancer (mCSPC)
  • Real-world treatment patterns and outcomes in advanced . . .
    Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based regimen This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium This


















中文字典-英文字典  2005-2009